Boardroom Alpha Digest: Tues, Mar 21

by | Mar 21, 2023

Executive News

  • Starbucks (SBUX) new CEO Laxman Narasimhan officially took the helm 2 weeks early and will lead the company’s annual shareholder meeting
  • NBT Bancorp Inc. (NBTB) director Joseph A. Santangelo will retire from the board following their annual meeting in May
  • Five Star Bancorp (FSBC) director David J. Lucchetti will also retire at their annual meeting

Activism

ICMYI: Latest podcast with the Activist Investor’s Michael Levin on the latest Universal Proxy and more

  • Ritchie Bros. Auctioneers (RBA) successfully completed its acquisition of IAA Inc. (IAA), fending off shareholder fights from Luxor Capital and against recommendations from ISS and GL

SPACs

  • Northern Revival Acquisition Corporation (NRAC) announced a $215M business combination with Australian “multi-faceted agricultural technology company” Braiin
  • Zura Bio Limited (ZURA) officially started trading on NASDAQ following the completion of its business combination with JATT Acquisition Corp. (JATT)
  • Corner Growth Acquisition Corp. II (TRON) extension approved 12 months until March 2024
  • MSD Acquisition Corp. (MSDA) to officially liquidate 3/29
  • Maxpro Capital Acquisition Corp. (JMAC) shareholders approved Apollonomics deal
  • KludeIn I Acquisition Corp. (INKA) and Near to close 3/22 and trade as NIR 3/23

SPAC Calendar

Recent Analysis

Daily SPAC Update – August 28, 2025

Meteora’s Vikas Mittal files for Bitcoin Infrastructure Acquisition $200M IPO. DT Cloud Acquisition Extension Approved. Corner Growth Asking Shareholders to Approve Capital Increase.

Daily SPAC Update – August 27, 2025

Another Crytpo SPAC Deal as Trump + Crypto.com Team Up. M3-Brigade IPOs Another SPAC. Calm Digital IPOs for $200M. Dynamix Ticker Change Pre-DeSPAC.

Daily SPAC Update – August 26, 2025

Alchemy + Cartiga and Inflection Point III + A1R WATER Deals Announced. Southport + Angel Studios Deal Approved. New Deal Deck for Ares II and Kodiak.

Daily SPAC Update – August 25, 2025

Southport Acquisition + Angel Studios Deal Vote. FG Merger II + Boxable Investor Presentation. DECA Securities Purchase Agreement. AParadise Acquisition Separate Trading.

AstroNova Settles Proxy Fight with Askeladden Capital

AstroNova and Askeladden Capital reached a cooperation agreement on August 21, 2025, following a contested proxy fight. The deal adds a new independent director, sets standstill provisions, and signals governance changes after years of underperformance.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.